AMC2 MED.B.090 Oncology

• ED Decision 2019/002/R found in: Aircrew (1178/2011) Part-FCL Part-MED Part-CC Part-ARA Part-ORA Part-DTO (Dec 2024)

AMC2 MED.B.090 Oncology ED Decision 2019/002/R (a)     Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that: (1)     after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2)     time appropriate to the type of tumour and primary treatment has elapsed; (3)     the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low; (4)     there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety; (5)     arrangements for an oncological follow-up have been made for an appropriate period of time. (b)     Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (c)      Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up. AMC2 MED.B.090 Oncology ED Decision 2019/002/R (a) Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that: (1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour and primary treatment has elapsed; (3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety; (5) arrangements for an oncological follow-up have been made for an appropriate period of time. (b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up. ##### AMC2 MED.B.090 Oncology *ED Decision 2019/002/R* (a) Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that: (1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour and primary treatment has elapsed; (3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety; (5) arrangements for an oncological follow-up have been made for an appropriate period of time. (b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.